Pharma Mar SA
MAD:PHM

Watchlist Manager

Pharma Mar SA

MAD:PHM

Watchlist

Dividends

Price: 79.4 EUR 1.15% Market Closed

Market Cap: 1.4B EUR

Have any thoughts about
Pharma Mar SA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	UnitedHealth Group Inc NYSE:UNH	Health Care
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Walmart Inc NYSE:WMT	Retail
US	Verizon Communications Inc NYSE:VZ	Telecommunication

Add Price Alert

Price Target:

Last Price: 79.4 EUR

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

PHM Alert

Pharma Mar SA

79.4

+0.9 (+1.15%)

52 Week Range	26.24 81.65
Price Target

We'll email you a reminder when the closing price reaches EUR.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Berkshire Hathaway Inc NYSE:BRK.A	US
	Bank of America Corp NYSE:BAC	US
	Mastercard Inc NYSE:MA	US
	UnitedHealth Group Inc NYSE:UNH	US
	Exxon Mobil Corp NYSE:XOM	US
	Pfizer Inc NYSE:PFE	US
	Palantir Technologies Inc NYSE:PLTR	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Walmart Inc NYSE:WMT	US
	Verizon Communications Inc NYSE:VZ	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Pharma Mar SA

What unique competitive advantages
does Pharma Mar SA hold over its rivals?

What risks and challenges
does Pharma Mar SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Pharma Mar SA.

What unique competitive advantages
does Pharma Mar SA hold over its rivals?

What risks and challenges
does Pharma Mar SA face in the near future?

Summarize the latest earnings call
of Pharma Mar SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Pharma Mar SA.

Provide P/S
for Pharma Mar SA.

Provide P/E
for Pharma Mar SA.

Provide P/OCF
for Pharma Mar SA.

Provide P/FCFE
for Pharma Mar SA.

Provide P/B
for Pharma Mar SA.

Provide EV/S
for Pharma Mar SA.

Provide EV/GP
for Pharma Mar SA.

Provide EV/EBITDA
for Pharma Mar SA.

Provide EV/EBIT
for Pharma Mar SA.

Provide EV/OCF
for Pharma Mar SA.

Provide EV/FCFF
for Pharma Mar SA.

Provide EV/IC
for Pharma Mar SA.

Show me price targets
for Pharma Mar SA made by professional analysts.

What are the Revenue projections
for Pharma Mar SA?

How accurate were the past Revenue estimates
for Pharma Mar SA?

What are the Net Income projections
for Pharma Mar SA?

How accurate were the past Net Income estimates
for Pharma Mar SA?

What are the EPS projections
for Pharma Mar SA?

How accurate were the past EPS estimates
for Pharma Mar SA?

What are the EBIT projections
for Pharma Mar SA?

How accurate were the past EBIT estimates
for Pharma Mar SA?

Compare the revenue forecasts
for Pharma Mar SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Pharma Mar SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Pharma Mar SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Pharma Mar SA compared to its peers.

Compare the P/E ratios
of Pharma Mar SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Pharma Mar SA with its peers.

Analyze the financial leverage
of Pharma Mar SA compared to its main competitors.

Show all profitability ratios
for Pharma Mar SA.

Provide ROE
for Pharma Mar SA.

Provide ROA
for Pharma Mar SA.

Provide ROIC
for Pharma Mar SA.

Provide ROCE
for Pharma Mar SA.

Provide Gross Margin
for Pharma Mar SA.

Provide Operating Margin
for Pharma Mar SA.

Provide Net Margin
for Pharma Mar SA.

Provide FCF Margin
for Pharma Mar SA.

Show all solvency ratios
for Pharma Mar SA.

Provide D/E Ratio
for Pharma Mar SA.

Provide D/A Ratio
for Pharma Mar SA.

Provide Interest Coverage Ratio
for Pharma Mar SA.

Provide Altman Z-Score Ratio
for Pharma Mar SA.

Provide Quick Ratio
for Pharma Mar SA.

Provide Current Ratio
for Pharma Mar SA.

Provide Cash Ratio
for Pharma Mar SA.

What is the historical Revenue growth
over the last 5 years for Pharma Mar SA?

What is the historical Net Income growth
over the last 5 years for Pharma Mar SA?

What is the current Free Cash Flow
of Pharma Mar SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Pharma Mar SA.

EV/EBIT
Enterprise Value to EBIT

-349.2

Current

11.4

Median

Industry

Lower than median

Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT

-349.2

Enterprise Value

1.3B EUR

EBIT

-3.7m EUR

All Countries

Forward Multiples

			Market Cap	EV/EBIT
ES		Pharma Mar SA MAD:PHM	1.4B EUR	-349.2
FR		Pharnext SCA OTC:PNEXF	6T USD	-216 971.5
US		Abbvie Inc NYSE:ABBV	310.2B USD	23.4
US		Amgen Inc NASDAQ:AMGN	142B USD	30.5
US		Gilead Sciences Inc NASDAQ:GILD	115B USD	10.1
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	101.6B USD	21.9
US	E	Epizyme Inc F:EPE	94.1B EUR	-501.1
AU		CSL Ltd ASX:CSL	134.4B AUD	24.6
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	78.5B USD	17
US	S	Seagen Inc F:SGT	39.3B EUR	-53
NL		argenx SE XBRU:ARGX	36B EUR	-79.8

				EBIT Growth	EV/EBIT to Growth
ES		Pharma Mar SA MAD:PHM	Average EV/EBIT: 21.3 Negative Multiple: -349.2	N/A	N/A
FR		Pharnext SCA OTC:PNEXF	Negative Multiple: -216 971.5	N/A	N/A
US		Abbvie Inc NYSE:ABBV	23.4	90%	0.3
US		Amgen Inc NASDAQ:AMGN	30.5	90%	0.3
US		Gilead Sciences Inc NASDAQ:GILD	10.1	32%	0.3
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	21.9	45%	0.5
US	E	Epizyme Inc F:EPE	Negative Multiple: -501.1	N/A	N/A
AU		CSL Ltd ASX:CSL	24.6	54%	0.5
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	17	42%	0.4
US	S	Seagen Inc F:SGT	Negative Multiple: -53	N/A	N/A
NL		argenx SE XBRU:ARGX	Negative Multiple: -79.8	N/A	N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

EV/EBIT

-586.2

2-Years Forward

EV/EBIT

33.6

3-Years Forward

EV/EBIT

18.2

	Franklin Covey Co NYSE:FC	36.4 USD -0.03%
	Mohawk Industries Inc NYSE:MHK	119.13 USD -0.03%
	Ardmore Shipping Corp NYSE:ASC	11.83 USD 4.6%
	ASGN Inc NYSE:ASGN	83.54 USD -0.39%
	Skyworks Solutions Inc NASDAQ:SWKS	89.16 USD 0.46%
	Weatherford International PLC NASDAQ:WFRD	68.25 USD 1.71%

	Johnson & Johnson NYSE:JNJ	143.655 USD -0.56%
	Bank of America Corp NYSE:BAC	43.75 USD -0.95%
	Mastercard Inc NYSE:MA	525.26 USD -0.53%
	Salesforce Inc NYSE:CRM	340.66 USD -0.87%
	Abbvie Inc NYSE:ABBV	175.83 USD 0.14%
	Home Depot Inc NYSE:HD	390.28 USD -0.59%

	Arista Networks Inc NYSE:ANET	113.22 USD 0.36%
	Visa Inc NYSE:V	315.99 USD -0.54%
	Texas Pacific Land Corp NYSE:TPL	1 126.6353 USD -0.57%
	KLA Corp NASDAQ:KLAC	642.06 USD 2.02%
	Manhattan Associates Inc NASDAQ:MANH	277.935 USD -0.83%
	Pinduoduo Inc NASDAQ:PDD	99.72 USD 0.21%

	Salesforce Inc NYSE:CRM	340.66 USD -0.87%
	Accenture PLC NYSE:ACN	356.61 USD -2.66%
	ServiceNow Inc NYSE:NOW	1 085.37 USD -0.54%
	EOG Resources Inc NYSE:EOG	119.18 USD 0.12%
	Copart Inc NASDAQ:CPRT	58.11 USD -0.19%
	Applied Materials Inc NASDAQ:AMAT	166.1517 USD 1.57%

Pharma Mar SA
MAD:PHM

EV/EBIT
Enterprise Value to EBIT

EV/EBIT Forward Multiples

See Also

Company

Help

Tools

Stocks

Pharma Mar SA MAD:PHM

EV/EBIT Enterprise Value to EBIT

EV/EBIT Forward Multiples

See Also

Company

Help

Tools

Stocks

Pharma Mar SA
MAD:PHM

EV/EBIT
Enterprise Value to EBIT